
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.66927
Pathology
Radiology
Oncology
From Breast to Orbit: A Case Report of Metastatic Breast Cancer With Orbital Involvement
Muacevic Alexander
Adler John R
AlMansour Alhanouf M 1
Almutairi Nada A 1
Abdul Hafiez Nafisa 2
Alkaiyat Mohammad 3
1 Oncology, King Saud Bin Abdulaziz University for Health Sciences College of Medicine, Riyadh, SAU
2 Oncology, Ministry of National Guard Health Affairs (MNGHA), Riyadh, SAU
3 Oncology, King Abdulaziz Medical City, Riyadh, SAU
Alhanouf M. AlMansour alhanoufmalmansour@gmail.com
15 8 2024
8 2024
16 8 e6692714 8 2024
Copyright © 2024, AlMansour et al.
2024
AlMansour et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/283760-from-breast-to-orbit-a-case-report-of-metastatic-breast-cancer-with-orbital-involvement
The approach to manage breast cancer has undergone a significant transformation, leading to longer survival rates. However, there is still a rise in metastasis occurring in less common locations such as the orbit. We report the case of a 40-year-old female diagnosed with luminal A, left-side breast cancer, back in September 2020. She presented with de novo metastatic diseases to the liver, bone, lung, and orbit. She received palliative radiation therapy (RT) to the orbit at the dose of 25 Gray (Gy) in five fractions, and follow-up brain magnetic resonance imaging (MRI) indicated a positive response to treatment with a slight reduction in the size of the left infraorbital lesion. Systemic treatment was started with hormonal therapy fulvestrant and luteinizing hormone-releasing hormone (LHRH), leuprolide, accompanied by palbociclib. As the incidence of ocular metastasis from breast cancer increases, oncologists need to be vigilant about symptoms and use appropriate diagnostic techniques.

targeted therapy
treatment
radiotherapy
orbital metastases
infiltrating ductal carcinoma
breast cancer
==== Body
pmcIntroduction

Orbital metastases are relatively uncommon, representing 1-13% of all orbital tumors and impacting approximately 2-5% of individuals with systemic malignancies [1-3]. They are frequently caused by breast cancer, followed by prostate cancer, lung cancer, cutaneous melanoma, kidney cancer, and gastrointestinal tract cancer [3-5]. Breast cancer accounts for approximately 30-50% of orbital metastases, with patients exhibiting diverse time intervals between the diagnosis of breast cancer and the onset of ocular metastasis. Within these cases, 40.4% of the patients manifested eye metastasis as the initial presentation of breast cancer, while 59.5% developed ocular metastasis either as the sole site of metastasis or concurrent with the progression of previously diagnosed breast cancer [6]. The purpose of this report is to present the case of orbital metastases as an incidental finding of breast cancer. 

Case presentation

Patient information, clinical finding, and diagnostic assessment

We report the case of a 40-year-old female who was diagnosed on September 27, 2020, with T1N1M1 (lungs, bone, liver, and orbit), infiltrating ductal carcinoma (IDC) of the left breast, Scarff-Bloom-Richardson (SBR) grade 2/3 (architectural score 3, nuclear grade 2, mitotic score 2), estrogen receptor (ER)/progesterone (PR) positive/human epidermal growth factor receptor 2 (HER-2) negative, and Ki-67 protein of 15%. The patient presented with severe back pain, and the bone scan revealed multiple bone metastases, including the right humerus, inferior scapula, and scapular spine extending to the acromion and the distal clavicle. She underwent genetic testing because of her age, and it showed AKT mutation (somatic), AKT1 c:49G>A (p.E17K), and BRCA gene testing was negative. Laboratory investigations revealed increased tumor marker CA 15-3=157 U/mL (normal ≤30 U/mL).

Treatment was started with hormonal therapy luteinizing hormone-releasing hormone (LHRH) analogs, leuprolide 7.5 mg every four weeks, fulvestrant 500 mg (days 1, 14, and 29) intramuscular and then 500 mg every four weeks, and anti-cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib 125 mg orally for 21 days, cycle every 28 days. Our patient was experiencing mild eye pain, which was insignificant, but the oncologist preferred to do brain magnetic resonance imaging (MRI) to rule out brain metastasis. A brain MRI was done on September 27, 2020, and it showed a left intraorbital intracoronal nodule representing orbital metastasis (Figure 1) and a right parietal bone lesion representing skull metastasis (Figure 2). There was no evidence of brain metastasis.

Figure 1 Brain MRI at diagnosis: left intracoronal nodule (9×6 mm) along the medial rectus muscle on the left side

MRI: magnetic resonance imaging

Figure 2 Brain MRI at diagnosis: right parietal bone lesion

MRI: magnetic resonance imaging

Therapeutic intervention and outcome of treatment

After a multidisciplinary discussion, the patient received palliative radiation therapy (RT) to the orbit and skull at a dose of 25 Gray (Gy) in five fractions. A follow-up brain MRI was done on January 7, 2021, and it showed an interval response to the treatment of the right parietal bone lesion (Figure 3) and a slightly reduced size of the left infraorbital lesion (Figure 4).

Figure 3 Brain MRI for follow-up post-radiotherapy: right parietal bony lesion shows reduced enhancement with surrounding edema

MRI: magnetic resonance imaging

Figure 4 Brain MRI for follow-up post-radiotherapy: reduction in the size of the left intraorbital intracoronal lesion (7×4 mm)

MRI: magnetic resonance imaging

Abdominal and pelvic computed tomography (CT) showed an interval improvement of metastatic liver lesions, and chest CT showed a significant improvement in lung metastasis. The tumor marker CA 15-3 decreased to 117 U/mL. After dental clearance, the patient started on denosumab 120 mg subcutaneously every four weeks. She was doing great in her last clinic visit which was on May 29, 2024, and her performance status was 1, and she was tolerating fulvestrant, palbociclib, and LHRH very well. Her last follow-up bone scan on November 21, 2023, showed stable heterogeneous radiotracer activity involving the dorsolumbar spine and sternum, with no new lesions identified. The recent CA 15-3 level decreased simultaneously to a normal level (13.7 U/mL), most likely corresponding to the therapeutic effect. Chest and abdominal scans were done on May 6, 2024, revealing stable disease.

Discussion

Metastatic orbital disease accounts for 1-13% of all orbital tumors, with an average time interval of 2-8.5 years from breast cancer diagnosis to the onset of ocular metastasis [1,7]. In our case, the orbital metastasis was incidentally diagnosed within a month of breast cancer diagnosis after a brain MRI was done to rule out brain metastases. Orbital metastasis can be attributed to the anatomy of the orbit that demonstrates limited lymphatic drainage, suggesting a systemic hematologic dissemination of the distant primary tumor [8]. As observed in our case, which is ER/PR sensitive, most primary tumors that originate from breast cancer and metastasize to the orbits are hormone-sensitive tumors, which can be explained by the cellular tropism caused by estrogen produced by the periorbital fat [7,9]. Although our case was diagnosed with IDC, it was reported that infiltrative lobular carcinoma (ILC) was five times more frequently associated with orbital metastases compared to IDC [10].

Orbital metastasis frequently presents with proptosis (52.3%), relative afferent pupillary defect (RAPD) (38.7%), and diplopia of the ipsilateral eye (35.5%) [11]. However, a retrospective study showed that only 0.7% of orbital metastasis from breast cancer were symptomatic [12]. In our case, the patient was asymptomatic, and the orbital metastasis was an incidental finding. MRI and a contrasted CT are useful diagnostic tools for detecting metastatic lesions; nevertheless, histological examination by fine needle aspiration or open surgical biopsy of the lesion is needed for the definitive diagnosis [13,14]. A systemic review of orbital metastasis demonstrated that incisional biopsy was preferred over fine needle aspiration (63.7% vs. 10.2%), respectively, while partial resection was preferred over complete resection, accounting for 16.6% and 9.5%, respectively [11].

Although there is a wide range of treatment modalities, including surgery, chemotherapy, hormonal therapy, or a combination of these approaches, orbital radiotherapy is the most effective treatment in controlling the size of the tumor and has been reported to significantly improve symptoms compared to not receiving radiotherapy [6,8,9,11,15]. Patients with orbital metastasis were reported to have a poor prognosis, with one-year survival rates highest in breast (57%) and carcinoid (53%) cancers compared to other highly aggressive tumors such as lung and liver carcinomas and malignant melanoma [11].

Conclusions

Metastatic spread from breast cancer to the orbit is a rare finding that is highly associated with poor prognosis. As orbital metastasis can be asymptomatic, it is highly recommended for healthcare professionals to perform full diagnostic workups at the time of initial diagnoses once the patient is symptomatic in order to detect any orbital metastases and provide appropriate treatment or close monitoring. Additionally, introducing new radiotherapy techniques for treating breast cancer with orbital metastasis can reveal new aspects for improving outcomes. Finally, we think it's crucial to report and share experiences with these cases due to the limited data available in this area.

Disclosures

Author Contributions

Human subjects: Consent was obtained or waived by all participants in this study. King Abdullah International Medical Research Center (KAIMRC) issued approval 0000026524.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Alhanouf M. AlMansour, Nada A. Almutairi, Nafisa Abdul Hafiez, Mohammad Alkaiyat

Acquisition, analysis, or interpretation of data:  Alhanouf M. AlMansour, Nada A. Almutairi, Nafisa Abdul Hafiez, Mohammad Alkaiyat

Drafting of the manuscript:  Alhanouf M. AlMansour, Nada A. Almutairi, Nafisa Abdul Hafiez, Mohammad Alkaiyat

Critical review of the manuscript for important intellectual content:  Alhanouf M. AlMansour, Nada A. Almutairi, Nafisa Abdul Hafiez, Mohammad Alkaiyat

Supervision:  Alhanouf M. AlMansour, Nada A. Almutairi, Nafisa Abdul Hafiez, Mohammad Alkaiyat
==== Refs
References

1 Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery Lecture, part 1 Ophthalmology Shields JA Shields CL Scartozzi R 997 1008 111 2004 15121380
2 An analysis of 2,480 space-occupying lesions of the orbit from 1976 to 2011 Ophthalmic Plast Reconstr Surg Bonavolontà G Strianese D Grassi P Comune C Tranfa F Uccello G Iuliano A 79 86 29 2013 23470516
3 Orbital metastases in Italy Int J Ophthalmol Magliozzi P Strianese D Bonavolontà P 1018 1023 8 2015 26558220
4 Orbital metastasis: clinical features, management and outcome Orbit Valenzuela AA Archibald CW Fleming B 153 159 28 2009 19839900
5 Clinical and imaging characteristics of orbital metastatic lesions among Egyptian patients Clin Ophthalmol Eldesouky MA Elbakary MA 1683 1687 9 2015 26392748
6 Eye metastasis in breast cancer: case report and review of literature Ecancermedicalscience Saad ES Bakri HM Rayan A Barakat D Khalel MM 1353 16 2022 35510138
7 Orbital metastases from breast cancer: a retrospective analysis of 28 cases Cancer Treat Res Commun Grajales-Alvarez R Gutierrez-Mata A 100184 24 2020 32575027
8 Orbital metastases of invasive lobular breast carcinoma Breast Dis Tsagkaraki IM Kourouniotis CD Gomatou GL Syrigos NK Kotteas EA 85 91 38 2019 31640079
9 Orbital metastases from breast cancer: a single institution case series J Surg Oncol Sindoni A Fama' F Vinciguerra P 170 175 122 2020 32297325
10 High frequency of lobular breast cancer in distant metastases to the orbit Cancer Med Raap M Antonopoulos W Dämmrich M 104 111 4 2015 25355547
11 Orbital metastases: a systematic review of clinical characteristics, management strategies, and treatment outcomes Cancers (Basel) Palmisciano P Ferini G Ogasawara C 94 14 2021 35008259
12 Orbital metastases from breast cancer: retrospective analysis at an academic cancer center Breast J Pierson TM Tebit EV El Sayed A Smolkin ME Dillon PM 447 450 22 2016 27143519
13 Metastases of systemic malignancies to the orbit: a major review Orbit Wladis EJ Lee KW Nazeer T 93 97 40 2021 32340504
14 Orbital metastasis secondary to breast cancer: a rare cause of unilateral external ophthalmoplegia Neuroophthalmology Karti O Ozdemir O Top Karti D Zengin MO Tatli S Kusbeci T Celebisoy N 181 183 45 2020 34188339
15 Breast carcinoma metastasis to the medial rectus muscle: case report Turk J Ophthalmol Yabaş Kızıloğlu Ö Paksoy Türköz F Totuk Gedar ÖM Mestanoğlu M Yapıcıer Ö 168 170 49 2019 31245980
